期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 248, 期 1-2, 页码 53-57出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2012.01.002
关键词
Multiple sclerosis; Biomarkers; Lipids; Anti-lipid antibodies
资金
- National Institutes of Health [AI075285, AI093903]
- National Multiple Sclerosis Society [RG4111A1]
- Harvard Medical School Office for Diversity and Community Partnership
- Swedish Research Council
Multiple sclerosis (MS) is an autoimmune disease that targets the central nervous system (CNS). MS initially follows a relapsing-remitting course (RRMS) in which acute attacks are followed by a complete recovery. Eventually, 65% of the RRMS patients go on to develop secondary progressive MS (SPMS), characterized by the progressive and irreversible accumulation of neurological disability. It has been proposed that the transition from RRMS to SPMS results from changes in the nature of the inflammatory response and the progressive accumulation of neurodegeneration. To date, however, there is no reliable method to monitor the activity of the different immune and neurodegenerative processes that contribute to MS pathology. Thus, there is a need for biomarkers useful for the diagnosis, treatment and monitoring of MS patients. In this review, we discuss the potential use of lipids and the immune response against them as biomarkers of inflammation and neurodegeneration for MS. (C) 2012 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据